Quick Answer
ENANTA PHARMACEUTICALS INC reported Net Income Loss of -$81.89 million for the year ending 2025.
- ENANTA PHARMACEUTICALS INC showed an increase of +29.4% in Net Income Loss from 2024 to 2025.
- This data is from ENANTA PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on November 19, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), ENANTA PHARMACEUTICALS INC's Net Income Loss has declined by 451.3%.
- Historical annual values: Fiscal year 2025: -$81.89 million | Fiscal year 2024: -$116.05 million | Fiscal year 2023: -$133.82 million | Fiscal year 2022: -$121.76 million | Fiscal year 2021: -$79.00 million | Fiscal year 2020: -$36.17 million | Fiscal year 2019: $46.38 million | Fiscal year 2018: $71.96 million | Fiscal year 2017: $17.71 million | Fiscal year 2016: $21.67 million | Fiscal year 2015: $78.99 million | Fiscal year 2014: $34.44 million | Fiscal year 2013: $9.63 million | Fiscal year 2012: $21.40 million | Fiscal year 2011: $23.31 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: